Food & Function · 2024 · 12 citations · 56 references
MedicineOncologyPharmacologyCancer PharmacologyCarcinogenesisMolecular OncologyCancer Stem CellsHepatocellular CarcinomaHepatocellular Carcinoma PharmacotherapyLiver CancerLiver DiseaseCell Cycle DynamicsCell Cycle InhibitionG0 Phase EntryG1 Phase ControlG1 Phase ProgressionLactoferrin ActivityLiver Progenitor CellsLiver Tumor Therapy
model, such as necrosis, ROS production, and the surge of facultative liver stem cells, and eventually, holo-bLf reduced the number of preneoplastic lesions. For an established HCC model, holo-bLf treatment significantly reduced HepG2 tumor burden in xenotransplanted mice. Finally, holo-bLf in combination with sorafenib, the advanced HCC first-line treatment, synergistically decreased HepG2 viability by arresting cells in the G0/G1 phase of the cell cycle. Our findings provide the first evidence suggesting that holo-bLf has the potential to prevent HCC or to be used in combination with treatments for established HCC.
56
Leonard D. Shultz, Bonnie Lyons, Lisa Burzenski et al. · The Journal of Immunology · 2005 · 1.7K citations · Full text